12. January 2010 00:15
AnaptysBio, Inc., a privately-held therapeutic antibody platform and
product company, today announced it has signed an agreement with Roche
for the development of novel antibody therapeutics.
“AnaptysBio’s proprietary SHM platform provides a powerful new approach
for evolving existing antibodies to meet challenging therapeutic design
goals such as those specified by Roche”
Under the terms of the agreement, AnaptysBio will be responsible for
generating novel antibodies using its proprietary somatic hypermutation
(SHM) platform. Roche will receive a worldwide license to develop and
commercialize antibodies optimized by AnaptysBio. In addition to a
signing fee paid by Roche, AnaptysBio will be eligible to receive
milestone payments and royalties upon product sales.
“AnaptysBio’s proprietary SHM platform provides a powerful new approach
for evolving existing antibodies to meet challenging therapeutic design
goals such as those specified by Roche,” said Tom Smart, chairman and
chief executive officer for AnaptysBio. “We look forward to assisting
Roche in building its pipeline of product possibilities as we also apply
the platform to generate our own novel product candidates.”
SOURCE AnaptysBio, Inc.,
Subscribe